Benjamin L. Palleiko
2023
In 2023, Benjamin L. Palleiko earned a total compensation of $2.4M as President, Chief Business Officer and Chief Financial Officer at Carbylan Therapeutics, a 29% decrease compared to previous year.
Compensation breakdown
| Bonus | $180,075 |
|---|---|
| Option Awards | $189,421 |
| Salary | $514,500 |
| Stock Awards | $1,524,224 |
| Other | $12,527 |
| Total | $2,420,747 |
Palleiko received $1.5M in stock awards, accounting for 63% of the total pay in 2023.
Palleiko also received $180.1K in bonus, $189.4K in option awards, $514.5K in salary and $12.5K in other compensation.
Rankings
In 2023, Benjamin L. Palleiko's compensation ranked 379th out of 2,238 executives tracked by ExecPay. In other words, Palleiko earned more than 83.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 379 out of 2,238 | 83rd |
Division Manufacturing | 210 out of 1,216 | 83rd |
Major group Chemicals And Allied Products | 146 out of 683 | 79th |
Industry group Drugs | 144 out of 654 | 78th |
Industry Pharmaceutical Preparations | 92 out of 470 | 80th |
Source: SEC filing on August 14, 2023.
Palleiko's colleagues
We found two more compensation records of executives who worked with Benjamin L. Palleiko at Carbylan Therapeutics in 2023.